A rare form of Guillain-Barré syndrome emerged after AstraZeneca vaccinations, raising questions about potential immune responses.
In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barré syndrome after individuals were vaccinated against COVID-19.
Both reports describe an unusual variant of Guillain-Barré syndrome characterized by prominent facial weakness. Seven cases were reported from a regional medical center in Kerala, India, where approximately 1.2 million people were vaccinated with the AstraZeneca COVID-19 vaccine. Four cases were reported from Nottingham, England, in an area in which approximately 700,000 people received the same vaccine. All eleven cases were among people who had received that vaccine 10-22 days earlier.
The frequency of Guillain-Barré syndrome in these areas was estimated to be up to 10 times greater than expected.
“If the link is causal it could be due to a cross-reactive immune response to the SARS-CoV-2 spike protein and components of the peripheral immune system,” wrote the authors of the report from England.
The authors of both articles stress that clinicians should be vigilant in looking for this rare neurological syndrome following the administration of COVID-19 vaccines.
References:
“Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine” by Boby V. Maramattom MD, DM, FRCP; Parameswaran Krishnan MD, DM; Reji Paul MD, DM, Sandeep Padmanabhan MD, DM; Soumya Cherukudal Vishnu Nampoothiri MD, DM, DNB; Akheel A. Syed MBBS, MRCP(UK), PhD, FRCP(Edin) and Halinder S. Mangat MD, MSc, FCNS, FCCM, 10 June 202, Annals of Neurology.
DOI: 10.1002/ana.26143
“Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination” by Christopher Martin Allen, Shelby Ramsamy, Alexander William Tarr, Patrick Jason Tighe, William Lucien Irving, Radu Tanasescu and Jonathan Rhys Evans, 10 June 202, Annals of Neurology.
DOI: 10.1002/ana.26144
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
2 Comments
How many “rare” serious adverse effects are scientists going to find?
Place your bets in the comments.
T H E
S P A R S P A N D E M I C
2025 – 2028
A Futuristic Scenario for Public Health Risk Communicators
“While the federal government appeared to have appropriately addressed concerns around the acute side effects of Corovax, the long-term, chronic effects of the vaccine were still largely unknown. Nearing the end of 2027, reports of new neurological symptoms began to emerge.
After showing no adverse side effects for nearly a year, several vaccine recipients slowly began to experience symptoms such as blurry vision, headaches, and numbness in their extremities. Due to the small number of these cases, the significance of their association with Corovax was never determined.
As of this writing in 2030, longitudinal studies initiated by the NIH at the beginning of the vaccination program have not reached the next round of data collection, so formal analysis on these symptoms has not yet been conducted. Furthermore, these cases arose from the initial cohort of vaccine recipients—those in high-risk populations, including those with other underlying health conditions—making it increasingly difficult to determine the extent to which these symptoms are associated with vaccination.
As these cases emerged, patients began filing for compensation under the PREP Act. Due to lingering uncertainties over possible links between vaccination and reported neurological symptoms, their compensation requests were placed on indefinite hold, pending further data analysis. This cohort, many of whom adamantly supported the Corovax vaccine initially, quickly took to social media to publicize their issues.”
…
They were fully aware this was likely to happen. So much for the “informed consent” and “science”.
Well I appear to be yet another case not listed as I contracted GBS from the astra zeneca vaccine also 8 reports in Ireland and anotherc7 that I’ve heard of